RxDoctor Payments Data

Constance Simons

Family · Holly Hill, SCNPI 1740496165

Payments from drug & device makers

$643in general payments, 2019–2025

Across 34 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$112
  • Lilly USA, LLC$101
  • Bayer$97
  • Xeris Pharmaceuticals, Inc.$75
  • AstraZeneca$61
  • Esperion Therapeutics, Inc.$31
  • plus $166 from 8 others

What the payments were for

  • Food & beverage$643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$643 in reported general payments places this provider in the 55th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$904
Medicare patients
20
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$81,499
JardianceEmpagliflozin99$68,654
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$56,310
MounjaroTirzepatide46$47,807
RybelsusSemaglutide42$41,218
JanuviaSitagliptin Phosphate46$39,229
EliquisApixaban40$29,297
TrulicityDulaglutide31$28,864
Soliqua 100-33Insulin Glargine/Lixisenatide27$26,188
LinzessLinaclotide38$23,732
Janumet XrSitagliptin Phos/Metformin Hcl26$19,416
FarxigaDapagliflozin Propanediol22$19,148
Synjardy XrEmpagliflozin/Metformin Hcl20$9,893
Rosuvastatin Calcium435$6,551
Spiriva HandihalerTiotropium Bromide12$5,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$112$122,717122 claims
Boehringer IngelheimJardiance, Synjardy Xr$20$78,548119 claims
Lilly USA, LLCMounjaro, Trulicity$101$76,67177 claims
MerckJanuvia, Janumet Xr$15$58,64572 claims
PfizerEliquis$19$29,29740 claims
AbbVieLinzess$24$23,73238 claims
AstraZenecaFarxiga, Symbicort$61$23,15834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,248 family providers in South Carolina.

Other family in Holly Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →